Early Change of Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients with Ulcerative Colitis Starting Anti-TNF Treatment
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Sun-Ho | - |
dc.contributor.author | Walshe, Margaret | - |
dc.contributor.author | Oh, Eun Hye | - |
dc.contributor.author | Hwang, Sung Wook | - |
dc.contributor.author | Park, Sang Hyoung | - |
dc.contributor.author | Yang, Dong-Hoon | - |
dc.contributor.author | Byeon, Jeong-Sik | - |
dc.contributor.author | Myung, Seung-Jae | - |
dc.contributor.author | Yang, Suk-Kyun | - |
dc.contributor.author | Greener, Tomer | - |
dc.contributor.author | Weizman, Adam, V | - |
dc.contributor.author | Silverberg, Mark S. | - |
dc.contributor.author | Ye, Byong Duk | - |
dc.date.accessioned | 2023-09-11T01:48:39Z | - |
dc.date.available | 2023-09-11T01:48:39Z | - |
dc.date.created | 2023-07-21 | - |
dc.date.issued | 2021-08 | - |
dc.identifier.issn | 1078-0998 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/190354 | - |
dc.description.abstract | Background: Up to 60% of patients with ulcerative colitis (UC) ultimately fail anti-tumor necrosis factor (TNF) treatment. We aimed to investigate early predictive markers of clinical and endoscopic outcomes in patients with UC who were anti-TNF-naive commencing anti-TNF treatment, with particular focus on changes in albumin and C-reactive protein levels in the first 2 weeks of treatment. Methods: We retrospectively investigated 210 patients with UC who started infliximab or adalimumab between 2009 and 2016 (male, 62.4%; median age at diagnosis, 37.9 years [interquartile range, 25.5-48.9 years]; median follow-up duration, 3.3 years [1.9-5.0 years]). Logistic and Cox proportional-hazards regressions were performed to identify variables associated with primary nonresponse (PNR), endoscopic outcomes, time-to-colectomy, and anti-TNF failure. Results: Forty-one patients (19.5%) experienced PNR; week 0/week 2 ratio serum albumin was associated with PNR (adjusted odds ratio [aOR], 1.8; 95% confidence interval [CI], 1.1 2.9, per interquartile range increase). Week 0/week 2 ratio albumin was also associated with endoscopic response (aOR, 0.28; 95% CI, 0.31-0.82) and endoscopic remission (aOR, 0.61; 95% CI, 0.39-0.96) at weeks 8 to 14, time-to-colectomy (adjusted hazard ratio, 2.12; 95% CI, 1.29-3.49) and time-to-anti-TNF failure (adjusted hazard ratio, 1.54; 95% CI, 1.22-1.96), regardless of age, disease severity, or in-patient status. Association with time-to-colectomy and anti-TNF failure was externally validated in an independent cohort of inpatients with UC starting infliximab. Conclusions: Change in serum albumin within the first 2 weeks of anti-TNF treatment is predictive of PNR, endoscopic outcomes, time-tocolectomy, and anti-TNF failure in patients with UC. Timely access to this biomarker enables early identification of patients with UC at risk of anti-TNF failure and may guide early optimization of anti-TNF treatment to improve disease outcomes. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | OXFORD UNIV PRESS INC | - |
dc.title | Early Change of Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients with Ulcerative Colitis Starting Anti-TNF Treatment | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Oh, Eun Hye | - |
dc.identifier.doi | 10.1093/ibd/izaa309 | - |
dc.identifier.scopusid | 2-s2.0-85107392311 | - |
dc.identifier.wosid | 000692553700018 | - |
dc.identifier.bibliographicCitation | INFLAMMATORY BOWEL DISEASES, v.27, no.9, pp.1452 - 1461 | - |
dc.relation.isPartOf | INFLAMMATORY BOWEL DISEASES | - |
dc.citation.title | INFLAMMATORY BOWEL DISEASES | - |
dc.citation.volume | 27 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 1452 | - |
dc.citation.endPage | 1461 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | CROHNS-DISEASE | - |
dc.subject.keywordPlus | INDUCTION THERAPY | - |
dc.subject.keywordPlus | INFLIXIMAB | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | MAINTENANCE | - |
dc.subject.keywordPlus | ADALIMUMAB | - |
dc.subject.keywordPlus | ANTIBODIES | - |
dc.subject.keywordPlus | REMISSION | - |
dc.subject.keywordPlus | COLECTOMY | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordAuthor | ulcerative colitis | - |
dc.subject.keywordAuthor | anti-TNF | - |
dc.subject.keywordAuthor | serum albumin | - |
dc.identifier.url | https://academic.oup.com/ibdjournal/article/27/9/1452/6017554 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.